NCODA Logo

The purpose of this PQI is to highlight processes that can be implemented to minimize delays when treating acute myeloid leukemia (AML) with combination venetoclax and hypomethylating agent (HMA) therapy. Additionally, it will review the optimization of venetoclax treatment initiation and ongoing patient management.